Demo Sign up Log In

Lineage Cell Therapeutics, Inc. Common Stock (LCTX)

R&D Expenses

$4.77M

Quarterly · Period ending: Jun 30, 2026 · USD

LCTX R&D Expenses

Latest reported$4.77Mperiod endingJun 30, 2026

Latest reported$4.77Mperiod endingJun 30, 2026

LCTX Quarterly R&D Expenses ($0.00 → $4.77M)

Quarterly R&D Expenses

High-resolution chart · PNG

LCTX r&d expenses history

Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.

Lineage Cell Therapeutics, Inc. Common Stock R&D Expenses — Quarterly (USD)
Period ending	R&D Expenses (USD)
Jun 30, 2001	541,894
Mar 31, 2001	553,892
Dec 31, 2000	675,729
Sep 30, 2000	847,035
Jun 30, 2000	930,147
Mar 31, 2000	909,930
Dec 31, 1999	1,100,521
Sep 30, 1999	2,000,000
Jun 30, 1999	1,100,000
Mar 31, 1999	700,000
Sep 30, 1998	900,000
Jun 30, 1998	600,000
Mar 31, 1998	900,000
Dec 31, 1997	900,000
Sep 30, 1997	700,000
Jun 30, 1997	800,000
Mar 31, 1997	400,000
Dec 31, 1996	500,000
Sep 30, 1996	400,000
Jun 30, 1996	0
Mar 31, 1996	0
Dec 31, 1995	0
Sep 30, 1995	200,000
Jun 30, 1995	600,000
Mar 31, 1995	400,000
Dec 31, 1994	500,000
Sep 30, 1994	300,000
Jun 30, 1994	300,000
Mar 31, 1994	100,000
Dec 31, 1993	0
Sep 30, 1993	0
Jun 30, 1993	0
Mar 31, 1993	0
Dec 31, 1992	0
Sep 30, 1992	0
Jun 30, 1992	0
Mar 31, 1992	0

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.